| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-142 |
Sentence |
denotes |
Mass spectrometric analysis of hepatitis C viral envelope protein E2 reveals extended microheterogeneity of mucin-type O-linked glycosylation. |
| T1 |
0-142 |
Sentence |
denotes |
Mass spectrometric analysis of hepatitis C viral envelope protein E2 reveals extended microheterogeneity of mucin-type O-linked glycosylation. |
| T1 |
0-142 |
Sentence |
denotes |
Mass spectrometric analysis of hepatitis C viral envelope protein E2 reveals extended microheterogeneity of mucin-type O-linked glycosylation. |
| TextSentencer_T2 |
143-270 |
Sentence |
denotes |
The infectious liver disease hepatitis C is caused by the small, enveloped, positive single-strand RNA hepatitis C virus (HCV). |
| T2 |
143-270 |
Sentence |
denotes |
The infectious liver disease hepatitis C is caused by the small, enveloped, positive single-strand RNA hepatitis C virus (HCV). |
| T2 |
143-270 |
Sentence |
denotes |
The infectious liver disease hepatitis C is caused by the small, enveloped, positive single-strand RNA hepatitis C virus (HCV). |
| TextSentencer_T3 |
271-358 |
Sentence |
denotes |
The HCV genome encodes for a single polyprotein precursor of ∼3010 amino acid residues. |
| T3 |
271-358 |
Sentence |
denotes |
The HCV genome encodes for a single polyprotein precursor of ∼3010 amino acid residues. |
| T3 |
271-358 |
Sentence |
denotes |
The HCV genome encodes for a single polyprotein precursor of ∼3010 amino acid residues. |
| TextSentencer_T4 |
359-507 |
Sentence |
denotes |
Host and cellular proteases co- and posttranslational process the precursor creating six nonstructural (NS) proteins and four structural components. |
| T4 |
359-507 |
Sentence |
denotes |
Host and cellular proteases co- and posttranslational process the precursor creating six nonstructural (NS) proteins and four structural components. |
| T4 |
359-507 |
Sentence |
denotes |
Host and cellular proteases co- and posttranslational process the precursor creating six nonstructural (NS) proteins and four structural components. |
| TextSentencer_T5 |
508-599 |
Sentence |
denotes |
Properly folded forms of the envelope proteins E1 and E2 form the associated E1-E2 complex. |
| T5 |
508-599 |
Sentence |
denotes |
Properly folded forms of the envelope proteins E1 and E2 form the associated E1-E2 complex. |
| T5 |
508-599 |
Sentence |
denotes |
Properly folded forms of the envelope proteins E1 and E2 form the associated E1-E2 complex. |
| TextSentencer_T6 |
600-732 |
Sentence |
denotes |
This complex represents a significant antigenic component at the viral surface that can interact with several target cell receptors. |
| T6 |
600-732 |
Sentence |
denotes |
This complex represents a significant antigenic component at the viral surface that can interact with several target cell receptors. |
| T6 |
600-732 |
Sentence |
denotes |
This complex represents a significant antigenic component at the viral surface that can interact with several target cell receptors. |
| TextSentencer_T7 |
733-837 |
Sentence |
denotes |
Extent and type of glycosylation is an important factor for virulence and escape from the immune system. |
| T7 |
733-837 |
Sentence |
denotes |
Extent and type of glycosylation is an important factor for virulence and escape from the immune system. |
| T7 |
733-837 |
Sentence |
denotes |
Extent and type of glycosylation is an important factor for virulence and escape from the immune system. |
| TextSentencer_T8 |
838-1023 |
Sentence |
denotes |
Detailed characterization of the glycosylated sites is helpful for the understanding of different phenotypes as well as for the development of E1/E2-related treatments of HCV infection. |
| T8 |
838-1023 |
Sentence |
denotes |
Detailed characterization of the glycosylated sites is helpful for the understanding of different phenotypes as well as for the development of E1/E2-related treatments of HCV infection. |
| T8 |
838-1023 |
Sentence |
denotes |
Detailed characterization of the glycosylated sites is helpful for the understanding of different phenotypes as well as for the development of E1/E2-related treatments of HCV infection. |
| TextSentencer_T9 |
1024-1189 |
Sentence |
denotes |
Here, we have investigated in detail the O-linked glycosylation of the HCV envelope protein E2 expressed in and isolated from human embryonic kidney (HEK 293) cells. |
| T9 |
1024-1189 |
Sentence |
denotes |
Here, we have investigated in detail the O-linked glycosylation of the HCV envelope protein E2 expressed in and isolated from human embryonic kidney (HEK 293) cells. |
| T9 |
1024-1189 |
Sentence |
denotes |
Here, we have investigated in detail the O-linked glycosylation of the HCV envelope protein E2 expressed in and isolated from human embryonic kidney (HEK 293) cells. |
| TextSentencer_T10 |
1190-1470 |
Sentence |
denotes |
Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures. |
| T10 |
1190-1470 |
Sentence |
denotes |
Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures. |
| T10 |
1190-1470 |
Sentence |
denotes |
Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures. |
| TextSentencer_T11 |
1471-1530 |
Sentence |
denotes |
Based on our data, Thr385 is probably glycosylated as well. |
| T11 |
1471-1530 |
Sentence |
denotes |
Based on our data, Thr385 is probably glycosylated as well. |
| T11 |
1471-1530 |
Sentence |
denotes |
Based on our data, Thr385 is probably glycosylated as well. |
| TextSentencer_T12 |
1531-1633 |
Sentence |
denotes |
In addition, we could show that Ser479 within the hyper variable region (HVR) I is not O-glycosylated. |
| T12 |
1531-1633 |
Sentence |
denotes |
In addition, we could show that Ser479 within the hyper variable region (HVR) I is not O-glycosylated. |
| T12 |
1531-1633 |
Sentence |
denotes |
In addition, we could show that Ser479 within the hyper variable region (HVR) I is not O-glycosylated. |
| TextSentencer_T13 |
1634-1717 |
Sentence |
denotes |
For most of these sites, different degrees of microheterogeneity could be verified. |
| T13 |
1634-1717 |
Sentence |
denotes |
For most of these sites, different degrees of microheterogeneity could be verified. |
| T13 |
1634-1717 |
Sentence |
denotes |
For most of these sites, different degrees of microheterogeneity could be verified. |
| TextSentencer_T14 |
1718-1840 |
Sentence |
denotes |
Concerning HCV E2, this is the first case of experimentally proven O-linked glycosylation in detail via mass spectrometry. |
| T14 |
1718-1840 |
Sentence |
denotes |
Concerning HCV E2, this is the first case of experimentally proven O-linked glycosylation in detail via mass spectrometry. |
| T14 |
1718-1840 |
Sentence |
denotes |
Concerning HCV E2, this is the first case of experimentally proven O-linked glycosylation in detail via mass spectrometry. |